Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
Public ClinicalTrials.gov record NCT00428389. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial Dose of 5 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study was designed to evaluate the safety and tolerability of switching from donepezil to an initial dose of 5cm\^2 rivastigmine patch formulation in patients with probable Alzheimer's Disease (MMSE 10-24). The study included a 5-week, open-label, randomized period followed by a 20-week open-label extension period. Patients were randomized to either an immediate switch from donepezil to rivastigmine patch formulation or to a switch to rivastigmine patch formulation following a 7-day withdrawal period.
Study identification
- NCT ID
- NCT00428389
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 262 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2007 (Type not available)
- Primary completion
- Feb 2008 (Actual)
- Completion
- Feb 2008 (Actual)
- Last update posted
- Jun 11, 2014
2007 – 2008
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dedicated Clinical Research | Sun City | Arizona | 85351 | — |
| ATP Clinical Research | Costa Mesa | California | 92626 | — |
| Margolin Brain Institute | Fresno | California | 93720 | — |
| Investigative site | Denver | Colorado | 80209 | — |
| Berma Research Group | Hialeah | Florida | 33016 | — |
| Sunrise Clinical Research | Hollywood | Florida | 33021 | — |
| Center for Clinical Trials | Venice | Florida | 34285 | — |
| Premiere Research Institute @ Palm Beach Neurology | West Palm Beach | Florida | 33407 | — |
| Medical Associates of North Georgia | Canton | Georgia | 30114 | — |
| Medical Associates of North Georgia | Cumming | Georgia | 30040 | — |
| Witham Health Services | Lebanon | Indiana | 46052 | — |
| Investigative site | Pittsfield | Massachusetts | 01201 | — |
| Rochester Center For Behavioral Medicine | Rochester Hills | Michigan | 48307 | — |
| Alzheimer's Research Corporation | Manchester | New Hampshire | 08759 | — |
| Investigative site | Long Branch | New Jersey | 07740 | — |
| Neurobehavioral Research, Inc | Cedarhurst | New York | 11516 | — |
| Eastside Comprehensive Medical Center | New York | New York | 10021 | — |
| Investigative site | Centerville | Ohio | 45459 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Investigative site | Eugene | Oregon | 97401 | — |
| The Clinical Trial Center | Jenkintown | Pennsylvania | 19046 | — |
| Senior Adults Specialty Research | Austin | Texas | 78757 | — |
| Investigative site | Bennington | Vermont | 05201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00428389, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2014 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00428389 live on ClinicalTrials.gov.